The global dry eye syndrome market is expected to reach $6.2 billion by 2024, research by Mordor Intelligence shows. Stock Advisor launched in February of 2002. See you at the top! According to the Lupus Foundation of America, up to 60% of those patients will develop lupus nephritis, or an inflammation of the kidneys that, if uncontrolled, can lead to kidney failure and even death. (adsbygoogle = window.adsbygoogle || []).push({}); Save my name, email, and website in this browser for the next time I comment. When the opening bell rang, the stock was already trading well into the green. When the opening bell rang, the stock was already trading well … {{ article.date }} {{ article.time }}, Edgar (US Regulatory) - 11/2/2020 4:06:28 PM, Edgar (US Regulatory) - 10/29/2020 9:00:57 AM, Edgar (US Regulatory) - 10/22/2020 5:16:15 PM, Edgar (US Regulatory) - 10/2/2020 5:02:43 PM, Edgar (US Regulatory) - 9/28/2020 6:07:52 AM, Edgar (US Regulatory) - 9/8/2020 6:01:21 AM, Edgar (US Regulatory) - 8/11/2020 4:05:41 PM, Edgar (US Regulatory) - 7/23/2020 4:53:15 PM, Edgar (US Regulatory) - 7/23/2020 4:06:36 PM, Edgar (US Regulatory) - 7/22/2020 4:23:45 PM, Edgar (US Regulatory) - 7/22/2020 4:18:10 PM, Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k), Aurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye Syndrome. Results are expected to be ... Aurinia Pharmaceuticals Is Now An Attractive Buyout Candidate. Trade Ideas Review: A Deep Dive Into What They Have To... Tradespoon Review: Is The Service Worth Your Money? While we don’t have very high hopes considering that offers haven’t been made as of yet, it would return value to shareholders if it does happen. As many as 1.5 million Americans suffer from systemic lupus erythematosus, an autoimmune disease primarily affecting women that causes inflammation in connective tissues. Unfortunately, we weren’t able to find any fundamental news that would suggest such gains. Aurinia Pharmaceuticals (AUPH) Stock: Tremendous Upside Ahead. At the moment (9:42), AUPH is trading at $3.72 per share after a gain of $0.11 per share (2.90%) thus far today. The market has speculated on an Aurinia takeover for a while, with news articles as far back as in 2016 mentioning a possible buyout.

This is a vast market with room for new treatment options. Adria Cimino grew up with her nose in a book and a love of storytelling. Join the CNA Finance mailing list below! Ultimately, they’re looking at the stock as a strong takeover target.

Another reason is a bet on a takeover by a larger pharmaceutical company eager to get its hands on new products. Featured Tips that will Help you to Save up for Your First... GulfMark Offshore (GLF) Stock: Takes A Dive Then Halted. Notify me of follow-up comments by email. With one product ready for FDA review and another close behind, this year might be a key moment for the company to attract a buyer. You have entered an incorrect email address! There are tons of trading tools out there, but none of them are quite like TradeMiner. (function() { document.write( Finally, we may have relationships with some of the companies or IR firms that represent companies mentioned within our works in which we are compensated in cash and or stock for consulting, investor relations, and Press Release services (click here for details). While we’re only minutes into the session, the stock has already seen some ups and some downs, but has maintained relatively strong gains. © In December, Aurinia raised $191.7 million in gross proceeds through an offering of common shares and plans to use the funds to pay for product launch activities as well as general corporate purposes. So let's talk products, and therefore revenue, first. Aurinia'…

According to the Lupus Foundation of America, up to 60% of those patients will develop lupus nephritis, or an inflammation of the kidneys that, if uncontrolled, can lead to kidney failure and even death. For the lupus indication, sales of voclosporin have been estimated from more than $1 billion to as high as $2.2 billion -- in either case, taking it into blockbuster territory. If you want to get in contact with me, leave a comment below or email me at.

The software doesn’t look at your... Write CSS OR LESS and hit save. The company said in its third-quarter financial report that it has the financial resources to fund the lupus nephritis program, conduct the dry eye clinical trial, continue a Phase 2 trial for a third voclosporin indication, and fund operations into the fourth quarter of 2020. We also have affiliate relationships with various companies where we earn a portion of the sales revenue that we refer. Below, we’ll talk about what we’re seeing from AUPH, why, and what we’ll be watching for ahead. (adsbygoogle = window.adsbygoogle || []).push({}); At the moment, investors in Aurinia Pharmaceuticals seem to be voicing the same opinions on both Twitter and StockTwits. Last year, an analyst at Mackie Research Capital predicted that voclosporin ophthalmic solution would generate $450 million in sales. By a twist of fate, she started her career writing about biotech in Boston and discovered that each company is the source of many fascinating stories.